The 2024 update of IUIS phenotypic classification of human inborn errors of immunity
- PMID: 41608113
- PMCID: PMC12829316
- DOI: 10.70962/jhi.20250002
The 2024 update of IUIS phenotypic classification of human inborn errors of immunity
Abstract
Here, we report the 2024 update of the phenotypic classification by the International Union of Immunological Societies (IUIS) expert committee (EC) on inborn errors of immunity (IEI), which accompanies and complements the 2024 genotypic classification. The aim of this classification is to help diagnosis for clinicians at the bedside and focuses on clinical features and basic laboratory phenotypes of specific IEI. In this update, 559 IEI are described, including 67 novel monogenic defects and 2 new phenocopies. This phenotypic classification is presented in the form of decision trees when possible, with essential clinical or immunological phenotype entries.
© 2025 Bousfiha et al.
Conflict of interest statement
Disclosures: I. Aksentijevich reports “other” from In Vitro Diagnostic Solutions during the conduct of the study. T. Morio reports personal fees from Takeda Pharmaceutical, CSL Behring, Japan Blood Product Organization, Asteras, Sanofi, Ono Pharma, and Amgen outside the submitted work. K.E. Sullivan reports personal fees from the Immune Deficiency Foundation outside the submitted work. T.R. Torgerson reports personal fees from Pharming healthcare and Takeda, and “other” from Eli Lilly outside the submitted work. I. Meyts reports grants from CSL-Behring, Takeda, and Octapharma, and “other” from Boehringer-Ingelheim outside the submitted work. No other disclosures were reported.
Figures
References
-
- Poli, M.C., Aksentijevich I., Bousfiha A., Cunningham-Rundles C., Hambleton S., Klein C., Morio T., Picard C., Puel A., Rezaei N., et al. 2025. Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee. J. Hum. Immun. 10.70962/jhi.20250003 - DOI
LinkOut - more resources
Full Text Sources